Svein Lien appointed ceo of Biotec Pharmacon
Lien has a financial background and extensive experience at technology and diagnostics businesses
Lien has a financial background and extensive experience at technology and diagnostics businesses, most recently as chief executive of Axis-Shield, a diagnostic company listed in London and Oslo.
Following divestment of Immunocorp Animal Health in 2008 and Immunocorp Consumer Health at the end of 2009 Biotec Pharmacon has narrowed its strategic focus to two core business areas: pharmaceutical development and marine biochemicals.
Pharmaceutical development is in the research and development phase, while Biotec Marine Biochemicals specialises in cold-adapted marine enzymes for the molecular biology and diagnostics markets.
You may also like
Research & Development
From lab to launch: transforming pharmaceutical formulation development with GEA’s CFC Lab Coater
A new generation of continuous film coating technology is giving R&D teams the speed, precision and scalability they need to take products from the laboratory to commercial production without the traditional bottlenecks
Manufacturing
Bristol Myers Squibb licenses Lonza ADC linker-payload technology for undisclosed target
BMS has secured exclusive access to Lonza’s SYNtecan linker-payload platform, alongside GlycoConnect and HydraSpace technologies, to advance development of an antibody-drug conjugate against an undisclosed target
Pharmaceutical
Ardena strengthens executive team to drive its next phase of growth
Ghent, Belgium, 4 May 2026 – Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, announces the appointments of Ben Ash as Chief Financial Officer and Henny Zijlstra as Chief Commercial Officer. These additions further strengthen Ardena’s executive leadership team as the company continues to scale its operations and commercial reach globally
Pharmaceutical
Backed by investments exceeding $1 billion, PCI Pharma Services announces major expansion of US sterile fill-finish and drug-device delivery combination capabilities
As pharma manufacturers prioritise US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging